BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
_256_384.jpg)
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
With the expansion, the hospital’s total bed capacity will rise from 380 to 539 beds
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Integrated multidisciplinary model positions Hyderabad as a growing referral hub for advanced pediatric care
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
Subscribe To Our Newsletter & Stay Updated
